The new platform integrates automated ADME assays, AI-driven pharmacokinetic modelling and compound logistics to enable earlier profiling of small molecules during hit identification, potentially reducing late-stage attrition and improving compound prioritisation in drug discovery programmes.
Ginkgo Bioworks has launched ADME-One™, a new integrated platform designed to help drug discovery teams assess small molecule compounds earlier and more efficiently in the development process.
The platform has been co-developed by Ginkgo Datapoints, Tangible Scientific and Inductive Bio, combining high-throughput ADME testing with artificial intelligence-powered human pharmacokinetic projections and integrated compound management. The platform also offers turnaround times measured in days rather than weeks, reducing costs to below typical industry pricing.
This launch follows the three companies’ strategic partnership announced in August 2025, which focused on deploying AI-driven, lab-in-the-loop workflows across the biopharmaceutical industry.
The platform also offers turnaround times measured in days rather than weeks, reducing costs to below typical industry pricing
ADME, which stands for absorption, distribution, metabolism and excretion, is a critical stage in evaluating whether drug compounds are likely to succeed in humans. Traditionally, comprehensive ADME profiling has been carried out later in development because of the high cost and complexity of generating data.
Ginkgo said the new platform is intended to shift that process much earlier, enabling researchers to screen entire compound series during hit identification rather than waiting until lead optimisation.
The company believes this could reduce wasted synthesis cycles, improve decision-making and lower the risk of late-stage failures.
Three companies combine expertise
ADME-One combines capabilities from all three partners into a single workflow.
Ginkgo Datapoints will carry out all five Tier 1 ADME assays, including microsomal stability, cell permeability, kinetic solubility, CYP inhibition and plasma protein binding from its automated laboratory in Boston.
Inductive Bio’s Compass platform will then use the resulting data to generate human pharmacokinetic projections and guide compound prioritisation using AI-powered modelling.
Tangible Scientific will manage compound intake, plating, tracking and logistics throughout the process.
Ginkgo Datapoints will carry out all five Tier 1 ADME assays, including microsomal stability, cell permeability, kinetic solubility, CYP inhibition and plasma protein binding from its automated laboratory in Boston
John Androsavich, General Manager at Ginkgo Datapoints, said the platform could significantly change how drug developers use ADME data.
“With ADME-One, we’re both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process,” he said. “For the first time, chemists can efficiently characterise the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands.”
Faster workflows and lower costs
This launch now comes as pharmaceutical companies in the US and Europe increasingly seek domestic research infrastructure amid concerns surrounding data sovereignty and the BIOSECURE Act.
Adham Chebbani, Co-founder of Tangible Scientific, said the platform addresses operational bottlenecks that continue to slow AI-enabled drug discovery.
“We are at a moment in the application of AI to medicine where discovery teams can generate and prioritise drug candidates faster than their physical operations can validate them,” he said. “Tangible’s role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised.”
We are at a moment in the application of AI to medicine where discovery teams can generate and prioritise drug candidates faster than their physical operations can validate them
Ginkgo also announced the appointment of Jonathan Grob as Vice President of Small Molecules within Ginkgo Datapoints. Grob previously held roles at Novartis and Valo Health and will help lead the company’s AI-enabled small molecule drug discovery strategy.
No comments yet